FrancophonIA/ELRC3.0 huggingface dataset:
English: Emtricitabine/Tenofovir disoproxil Mylan contains lactose
Croatian: Emtricitabin/tenofovirdizoproksil Mylan sadržava laktozu
English: AUC: ↓ 4% (↓ 9 to ↑ 0) Cmax: ↓ 6% (↓ 13 to ↑ 0) Cmin: ↓ 2% (↓ 9 to ↑ 6)
Croatian: AUC: ↓ 4% (od ↓ 9 do ↑ 0) Cmax: ↓ 6% (od ↓ 13 do ↑ 0) Cmin: ↓ 2% (od ↓ 9 do ↑ 6)
English: Contains: lactose monohydrate.
Croatian: Sadržava laktozu hidrat.
English: Interrupting use of Emtricitabine/tenofovir disoproxil should also be considered in case of progressive decline of renal function when no other cause has been identified.
Croatian: Prekid primjene emtricitabin/tenofovirdizoproksila također treba razmotriti u slučaju progresivnog slabljenja funkcije bubrega ako se nije utvrdio ni jedan drugi uzrok.
English: The pharmacokinetics of emtricitabine/tenofovir disoproxil have not been studied in subjects with hepatic impairment.
Croatian: Farmakokinetika emtricitabin/tenofovirdizoproksila nije ispitana u ispitanika s oštećenjem funkcije jetre.
English: Cmin: ↑ 45% (↑ 27 to ↑ 64)
Croatian: Cmin: ↑ 45% (od ↑ 27 do ↑ 64)
English: AUC: ↑ 96% (↑ 74 to ↑ 121) Cmax: ↑ 68% (↑ 54 to ↑ 84) Cmin: ↑ 118% (↑ 91 to ↑ 150)
Croatian: AUC: ↑ 96% (od ↑ 74 do ↑ 121) Cmax: ↑ 68% (od ↑ 54 do ↑ 84) Cmin: ↑ 118% (od ↑ 91 do ↑ 150)
English: The increased exposure of tenofovir could potentiate tenofovir associated adverse events, including renal disorders.
Croatian: Povećana izloženost tenofoviru može pojačati nuspojave povezane s tenofovirom, uključujući poremećaje bubrega.
English: Darunavir/Ritonavir/Tenofovir disoproxil (300 mg q.d./100 mg q.d./245 mg q.d.)
Croatian: Darunavir/ritonavir/ tenofovirdizoproksil (300 mg q.d./100 mg q.d./245 mg q.d.)
English: Pre-exposure prophylaxis
Croatian: Predekspozicijska profilaksa
English: There is insufficient information on the effects of emtricitabine and tenofovir in newborns/infants.
Croatian: Nema dovoljno podataka o učincima emtricitabina i tenofovira u novorođenčadi/dojenčadi, stoga se emtricitabin/tenofovirdizoproksil ne bi trebao primjenjivati tijekom dojenja.
English: PrEP Checklist for prescribers:
Croatian: Lista provjere za propisivače kod predekspozicijske profilakse:
English: Ethinyl oestradiol:
Croatian: Etinilestradiol:
English: You do not need to take another tablet if you were sick more than 1 hour after taking this medicine.
Croatian: Drugu tabletu ne trebate uzimati ako ste povraćali nakon što je prošlo više od 1 sata po uzimanju lijeka Emtricitabin/tenofovirdizoproksil Mylan .
English: Brilliant blueFCF Aluminum lake (E133) Iron oxide yellow (E172)
Croatian: žuti željezov oksid (E172)
English: • The active substances are emtricitabine and tenofovir disoproxil.
Croatian: • Djelatne tvari su emtricitabin i tenofovirdizoproksil.
English: The recommended dose of Emtricitabine/Tenofovir disoproxil Mylan to treat HIV is:
Croatian: Preporučena doza lijeka Emtricitabin/tenofovirdizoproksil Mylan za liječenje HIV-a:
English: HIV paediatric renal educational brochure:
Croatian: Edukacijska brošura o HIV-u i renalnoj funkciji u djece:
English: How to take Emtricitabine/Tenofovir disoproxil Mylan 4.
Croatian: Kako uzimati lijek Emtricitabin/tenofovirdizoproksil Mylan 4.
English: AUC: ↑ 6% (↓ 1 to ↑ 13) Cmax: ↑13% (↑ 1 to ↑ 27) Cmin: NC
Croatian: AUC: ↑ 6% (od ↓ 1 do ↑ 13) Cmax: ↑ 13% (od ↑ 1 do ↑ 27) Cmin: NI
English: • joint stiffness
Croatian: • ukočenost zglobova
English: Only samples from subjects randomised to emtricitabine/tenofovir disoproxil were evaluated for detectable plasma or intracellular tenofovir disoproxil-DP levels.
Croatian: Mjerljive razine tenofovirdizoproksil-DP-a u plazmi ili unutar stanica bile su procijenjene samo u uzorcima ispitanika randomiziranih na primanje emtricitabin/tenofovirdizoproksila.
English: AUC: ↑ 81% (↑ 68 to ↑ 94) Cmax: ↑ 77% (↑ 53 to ↑ 104) Cmin: ↑ 121% (↑ 100 to
Croatian: AUC: ↑ 81% (↑ 68 do ↑ 94) Cmax: ↑ 77% (↑ 53 do ↑ 104) Cmin: ↑ 121% (↑ 100 do ↑ 143)
English: Cmin: ↑ 48% (↑ 34 to ↑ 63)
Croatian: Cmin: ↑ 48% (od ↑ 34 do ↑ 63)
English: Cmax: ↑ 25% (↑ 8 to ↑ 45) Cmin: ↔
Croatian: Cmax: ↑ 25% (od ↑ 8 do ↑ 45) Cmin: ↔
English: Lamivudine and emtricitabine/tenofovir disoproxil should not be administered concomitantly (see section 4.4).
Croatian: Lamivudin i emtricitabin/tenofovirdizoproks il ne smiju se primjenjivati istovremeno (vidjeti dio 4.4).
English: AUC: ↑ 65% (↑ 59 to ↑ 71) Cmax: ↑ 61% (↑ 51 to ↑ 72) Cmin: ↑ 115% (↑ 105 to
Croatian: AUC: ↑ 65% (↑ 59 do ↑ 71) Cmax: ↑ 61% (↑ 51 do ↑ 72) Cmin: ↑ 115% (↑ 105 do ↑ 126)
English: AUC: ↓ 4% (↓ 15 to ↑ 8) Cmax: ↑ 102% (↓ 96 to ↑ 108) Cmin: NC
Croatian: AUC: ↓ 4% (od ↓ 15 do ↑ 8) Cmax: ↑ 102% (od ↓ 96 do ↑ 108) Cmin: NI
English: Co-administration of emtricitabine/tenofovir disoproxil and didanosine is not recommended (see section 4.4).
Croatian: Ne preporučuje se istovremena primjena emtricitabin/tenofovirdizoproks ila i didanozina (vidjeti dio 4.4).
English: The mean rate of lumbar spine bone gain at week 48 was similar between the tenofovir disoproxil treatment group and the stavudine or zidovudine treatment group.
Croatian: U 48. tjednu, srednja vrijednost stope povećanja BMD-a u području lumbalne kralježnice u skupini koja je primala tenofovirdizoproksil bila je slična onoj skupine koja je primala stavudin ili zidovudin.
English: Adefovir dipivoxil and emtricitabine/tenofovir disoproxil should not be administered concomitantly (see section 4.4).
Croatian: Adefovirdipivoksil i emtricitabin/tenofovirdizoproks il ne smiju se primjenjivati istovremeno (vidjeti dio 4.4).
English: • Bone problems (sometimes resulting in fractures) may also occur due to damage to kidney tubule cells
Croatian: Tegobe s kostima (koje ponekad dovode do prijeloma) mogu se također pojaviti zbog oštećenja stanica bubrežnih kanalića (vidjeti dio 4, Moguće nuspojave).
English: 1 This adverse reaction may occur as a consequence of proximal renal tubulopathy.
Croatian: 1 Ova nuspojava može nastati kao posljedica proksimalne bubrežne tubulopatije.
English: AUC: ↓ 3% (↓ 8% to ↑ 15) Cmax: ↓ 24% (↓ 44 to ↓ 12) Cmin: NC
Croatian: AUC: ↓ 3% (od ↓ 8% do ↑ 15) Cmax: ↓ 24% (od ↓ 44 do ↓ 12) Cmin: NI
English: Emtricitabine/Tenofovir disoproxil Mylan 200 mg/245 mg film-coated tablets emtricitabine/tenofovir disoproxil
Croatian: Emtricitabin/tenofovirdizoproksil Mylan 200 mg/245 mg filmom obložene tablete emtricitabin/tenofovirdizoproksil
English: Alternative treatment regimens should be considered for patients with osteoporosis that are at a high risk for fractures.
Croatian: U pacijenata s osteoporozom i visokim rizikom od prijeloma potrebno je razmotriti druge režime liječenja.
English: AUC: ↑ 26% (↑ 20 to ↑ 32) Cmax: ↓ 5% (↓ 11 to ↑ 1) Cmin: NC
Croatian: AUC: ↑ 26% (od ↑ 20 do ↑ 32) Cmax: ↓ 5% (od ↓ 11 do ↑ 1) Cmin: NI
English: If serum phosphate is < 1.5 mg/dL (0.48 mmol/L) or creatinine clearance is decreased to < 50 mL/min in any patient receiving, emtricitabine/tenofovir disoproxil renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Croatian: Ako su u bilo kojeg pacijenta koji prima emtricitabin/tenofovirdizoproksil fosfati u serumu < 1,5 mg/dl (0,48 mmol/l) ili se klirens kreatinina smanji na < 50 ml/min, unutar jednoga tjedna treba ponovno procijeniti funkciju bubrega, kao i izmjeriti koncentracije glukoze u krvi, kalija u krvi i glukoze u mokraći (vidjeti dio 4.8, proksimalna tubulopatija).
English: AUC: ↑ 4% (↓ 3 to ↑ 11) Cmax: ↑ 3% (↓ 3 to ↑ 9) Cmin: NC
Croatian: AUC: ↑ 4% (od ↓ 3 do ↑ 11) Cmax: ↑ 3% (od ↓ 3 do ↑ 9) Cmin: NI
English: Incidence per 100 person-years (95% CI) 1.99 (1.49, 2.62) Relative Risk Reduction (95% CI)
Croatian: Serokonverzije / Na Incidencija na 100 osobagodina (95 % CI) Smanjenje relativnog rizika (95 % CI)
English: How to take Emtricitabine/Tenofovir disoproxil Mylan
Croatian: Kako uzimati Emtricitabin/tenofovirdizoproksil Mylan
English: AUC: ↓ 11% (↓ 14 to ↓ 7) Cmax: ↓ 7% (↓ 13 to ↓ 0) Cmin: NC
Croatian: AUC: ↓ 11% (od ↓ 14 do ↓ 7) Cmax: ↓ 7% (od ↓ 13 do ↓ 0) Cmin: NI
English: If serum phosphate is < 1.5 mg/dL (0.48 mmol/L) or creatinine clearance is decreased to < 60 mL/min in any individual receiving emtricitabine/tenofovir disoproxil for pre-exposure prophylaxis, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Croatian: Ako su u bilo koje osobe koja prima emtricitabin/tenofovirdizoproksil za predekspozicijsku profilaksu fosfati u serumu < 1,5 mg/dL (0,48 mmol/l) ili se klirens kreatinina smanji na < 60 ml/min, unutar jednoga tjedna treba ponovno ocijeniti funkciju bubrega, kao i izmjeriti koncentracije glukoze u krvi, kalija u krvi i glukoze u mokraći (vidjeti dio 4.8, proksimalna tubulopatija).
English: If vomiting occurs within 1 hour of taking Emtricitabine/Tenofovir disoproxil Mylan, another tablet should be taken.
Croatian: Ako nastupi povraćanje, a prošlo je manje od 1 sata od uzimanja lijeka Emtricitabin/tenofovirdizoproksil Mylan, treba uzeti drugu tabletu.
English: AUC: ↑ 5% (↓ 2 to ↑ 13) Cmax: ↑ 5% (↓ 3 to ↑ 14) Cmin: NC
Croatian: AUC: ↑ 5% (od ↓ 2 do ↑ 13) Cmax: ↑ 5% (od ↓ 3 do ↑ 14) Cmin: NI
English: Sofosbuvir: AUC: ↔ Cmax: ↓ 30% Cmin: N/A
Croatian: AUC: ↔ Cmax: ↓ 30% Cmin: N/P
English: Emtricitabine/Tenofovir disoproxil (200 mg/245 mg q.d.)
Croatian: Emtricitabin/tenofovirdizoproksil (200 mg/245 mg q.d.)
English: AUC: ↑ 39% (↑ 33 to ↑ 44) Cmax: ↑ 55% (↑ 45 to ↑ 66) Cmin: ↑ 52% (↑ 45 to ↑ 59)
Croatian: AUC: ↑ 39% (↑ 33 do ↑ 44) Cmax: ↑ 55% (↑ 45 do ↑ 66) Cmin: ↑ 52% (↑ 45 do ↑ 59)
English: However, it was negative in an in vivo mouse bone marrow micronucleus assay.
Croatian: Međutim, rezultati su bili negativni u mikronukleus testu in vivo na koštanoj srži miša.
English: AUC: ↓ 5% (↓ 9 to ↓ 1) Cmax: ↓ 11% (↓ 17 to ↓ 5) Cmin: NC
Croatian: AUC: ↓ 5% (od ↓ 9 do ↓ 1) Cmax: ↓ 11% (od ↓ 17 do ↓ 5) Cmin: NI
English: AUC: ↑ 50% (↑ 42 to ↑ 59) Cmax: ↑ 64% (↑ 54 to ↑ 74) Cmin: ↑ 59% (↑ 49 to ↑ 70)
Croatian: AUC: ↑ 50% (od ↑ 42 do ↑ 59) Cmax: ↑ 64% (od ↑ 54 do ↑ 74) Cmin: ↑ 59% (od ↑ 49 do ↑ 70)
English: How to store Emtricitabine/Tenofovir disoproxil Mylan 6.
Croatian: Kako čuvati lijek Emtricitabin/tenofovirdizoproksil Mylan 6.
English: Protease inhibitors Atazanavir/Ritonavir/Tenofovir disoproxil (300 mg q.d.
Croatian: Antiretrovirusni lijekovi Inhibitori proteaze Atazanavir/ritonavir/ tenofovirdizoproksil (300 mg q.d./100 mg q.d./245 mg q.d.)
English: Emtricitabine/tenofovir disoproxil
Croatian: Emtricitabin/tenofovirdizoproksil
English: The recommended dose of Emtricitabine/Tenofovir disoproxil Mylan to reduce the risk of getting HIV is:
Croatian: Preporučena doza lijeka Emtricitabin/tenofovirdizoproksil Mylan za smanjivanje rizika od dobivanja HIV-a:
English: AUC: ↑ 40% (↑ 34 to ↑ 46) Cmax: ↑ 44% (↑ 33 to ↑ 55) Cmin: ↑ 84% (↑ 76 to ↑ 92)
Croatian: AUC: ↑ 40% (↑ 34 do ↑ 46) Cmax: ↑ 44% (↑ 33 do ↑ 55) Cmin: ↑ 84% (↑ 76 do ↑ 92)
English: If serum phosphate is confirmed to be < 3.0 mg/dL (0.96 mmol/L) in any paediatric patient receiving Emtricitabine/tenofovir disoproxil, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Croatian: Ako su u bilo kojeg pedijatrijskog pacijenta koji prima emtricitabin/tenofovirdizoproksil fosfati u serumu < 3,0 mg/dl (0,96 mmol/l), unutar jednog tjedna treba ponovno procijeniti funkciju bubrega, kao i izmjeriti koncentracije glukoze u krvi, kalija u krvi i glukoze u mokraći (vidjeti dio 4.8, proksimalna tubulopatija).
English: AUC: ↓ 4% (↓ 32 to ↑ 34) Cmax: ↓ 5% (↓ 27 to ↑ 24) Cmin: NC
Croatian: AUC: ↓ 4% (od ↓ 32 do ↑ 34) Cmax: ↓ 5% (od ↓ 27 do ↑ 24) Cmin: NI
English: Cmin: ↑ 42% (↑ 34 to ↑ 49)
Croatian: Cmin: ↑ 42% (od ↑ 34 do ↑ 49)
English: AUC: ↑ 98% (↑ 77 to ↑ 123) Cmax: ↑ 79% (↑ 56 to ↑ 104) Cmin: ↑ 163% (↑ 137 to ↑
Croatian: AUC: ↑ 98% (od ↑ 77 do ↑ 123) Cmax: ↑ 79% (od ↑ 56 do ↑ 104) Cmin: ↑ 163% (od ↑ 137 do ↑ 197)
English: While taking Emtricitabine/Tenofovir disoproxil Mylan to treat HIV or to reduce the risk of getting HIV:
Croatian: Dok uzimate lijek Emtricitabin/tenofovirdizoproksil Mylan za liječenje HIV-a ili smanjenje rizika od dobivanja HIV-a:
English: AUC: ↑ 40% (↑ 34 to ↑ 45) Cmax: ↑ 46% (↑ 39 to ↑ 54) Cmin: ↑ 70% (↑ 61 to ↑ 79)
Croatian: AUC: ↑ 40% (↑ 34 do ↑ 45) Cmax: ↑ 46% (↑ 39 do ↑ 54) Cmin: ↑ 70% (↑ 61 do ↑ 79)
English: THE SIGHT AND REACH OF CHILDREN
Croatian: I DOHVATA DJECE
English: • pain in the abdomen (tummy) caused by inflammation of the pancreas
Croatian: • bol u trbuhu prouzročena upalom gušterače
English: INFORMATION IN BRAILLE Emtricitabine/Tenofovir disoproxil Mylan 17.
Croatian: 16. PODACI NA BRAILLEOVOM PISMU Emtricitabin/tenofovirdizoproksil Mylan
English: AUC: ↓ 7% (↓ 13 to ↓ 1) Cmax: ↓ 11% (↓ 20 to ↑ 1) Cmin: NC
Croatian: AUC: ↓ 7% (od ↓ 13 do ↓ 1) Cmax: ↓ 11% (od ↓ 20 do ↑ 1) Cmin: NI
English: Each film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg of tenofovir disoproxil maleate).
Croatian: Jedna filmom obložena tableta sadrži 200 mg emtricitabina i 245 mg tenofovirdizoproksila (što odgovara 300 mg tenofovirdizoproksilmaleata).
English: AUC: ↓ 4% (↓ 7 to ↓ 1) Cmax: ↓ 4% (↓ 9 to ↑ 2) Cmin: NC
Croatian: AUC: ↓ 4% (od ↓ 7 do ↓ 1) Cmax: ↓ 4% (od ↓ 9 do ↑ 2) Cmin: NI
English: AUC: ↓ 1% (↓ 8 to ↑ 6) Cmax: ↑ 7% (↓ 6 to ↑ 22) Cmin: NC
Croatian: AUC: ↓ 1% (od ↓ 8 do ↑ 6) Cmax: ↑ 7% (od ↓ 6 do ↑ 22) Cmin: NI
English: Before taking Emtricitabine/Tenofovir disoproxil Mylan to reduce the risk of getting HIV:
Croatian: Prije uzimanja lijeka Emtricitabin/tenofovirdizoproksil Mylan radi smanjenja rizika od dobivanja HIV-a:
English: AUC: ↓ 2% (↓ 5 to ↑ 0) Cmax: ↓ 1% (↓ 7 to ↑ 6) Cmin: NC
Croatian: AUC: ↓ 2% (od ↓ 5 do ↑ 0) Cmax: ↓ 1% (od ↓ 7 do ↑ 6) Cmin: NI
English: Emtricitabine/Tenofovir disoproxil Mylan.
Croatian: Emtricitabin/tenofovirdizoproksil Mylan.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg of tenofovir disoproxil maleate).
Croatian: 2. KVALITATIVNI I KVANTITATIVNI SASTAV Jedna filmom obložena tableta sadržava 200 mg emtricitabina i 245 mg tenofovirdizoproksila (što odgovara 300 mg tenofovirdizoproksilmaleata ili 136 mg tenofovira).
English: Sofosbuvir/Velpatasvir/ Voxilaprevir (400 mg/100 mg/ 100 mg+100 mg q.d.
Croatian: Sofosbuvir/velpatasvir/ voksilaprevir (400 mg/100 mg/ 100 mg+100 mg q.d.)3 + Darunavir (800 mg q.d.) + Ritonavir (100 mg q.d.) +
English: Hepatic impairment
Croatian: glavobolja omaglica
English: Lamivudine/Tenofovir disoproxil
Croatian: Lamivudin/tenofovirdizoproksil
English: Tel: + 39 02 612 46921
Croatian: Mylan Italia S.r.l. Tel: + 39 02 612 46921
English: WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
Croatian: OD LIJEKA, AKO JE POTREBNO
English: ORAL CONTRACEPTIVES Norgestimate/Ethinyl oestradiol /Tenofovir disoproxil
Croatian: Norgestimat/etinilestradiol/ tenofovirdizoproksil
English: Only Case or Cohort samples from subjects randomised to either tenofovir disoproxil 245 mg or emtricitabine/tenofovir disoproxil were evaluated for detectable plasma tenofovir levels.
Croatian: Mjerljive razine tenofovira u plazmi bile su ispitane samo u uzorcima ‚slučajeva' i ‚kohorte' uzetih od ispitanika randomiziranih ili u skupinu koja je primala tenofovirdizoproksil u dozi od 245 mg ili u skupinu koja je primala emtricitabin/tenofovirdizoproksil.
English: AUC: ↓ 9% (↓ 16 to ↓ 1) Cmax: ↓ 7% (↓ 22 to ↑ 11) Cmin: NC
Croatian: AUC: ↓ 9% (od ↓ 16 do ↓ 1) Cmax: ↓ 7% (od ↓ 22 do ↑ 11) Cmin: NI
English: STATEMENT OF ACTIVE SUBSTANCES
Croatian: 3. POPIS POMOĆNIH TVARI
English: The safety of tenofovir disoproxil when used with ledipasvir/sofosbuvir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.
Croatian: Sigurnost tenofovirdizoproksila prilikom istovremene primjene s ledipasvirom/sofosbuvirom i farmakokinetičkim pojačivačem (npr. ritonavirom ili kobicistatom) nije ustanovljena.
English: BOTTLE LABEL
Croatian: Tablični prikaz nuspojava
English: The safety of tenofovir disoproxil when used with sofosbuvir/velpatasvir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.
Croatian: Sigurnost tenofovirdizoproksila prilikom istovremene primjene sa sofosbuvirom/velpatasvirom i farmakokinetičkim pojačivačem (npr. ritonavirom ili kobicistatom) nije ustanovljena.
English: Individuals should be re-confirmed to be HIV-negative at frequent intervals (e.g. at least every 3 months) using a combined antigen/antibody test while taking emtricitabine/tenofovir disoproxil for pre-exposure prophylaxis.
Croatian: Dok uzimaju emtricitabin/tenofovirdizoproksil radi predekspozicijske profilakse, te se osobe trebaju često testirati (npr. najmanje svaka 3 mjeseca) s pomoću kombiniranog testa antigen-protutijelo kako bi se potvrdilo da su i dalje HIV-negativne.
English: Age (Yrs), Mean (SD) Race, N (%) Black/African American White Mixed/Other Asian Hispanic/Latino Ethnicity, N (%) Sexual Risk Factors at Screening
Croatian: Hispano/Latino etnička pripadnost, N (%) Spolni čimbenici rizika na probiru Broj partnera u prethodnih 12 tjedana, srednja vrijednost (SD)
English: Paediatrics with renal impairment:
Croatian: Pedijatrijska populacija s oštećenjem bubrega:
English: Darunavir: AUC: ↔ Cmax: ↔ Cmin: ↓ 34%
Croatian: AUC: ↔ Cmax: ↔ Cmin: ↓ 34%
English: An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy.
Croatian: Tijekom antiretrovirusne terapije može doći do povećanja tjelesne težine i razine lipida i glukoze u krvi.
English: While taking Emtricitabine/Tenofovir disoproxil Mylan to reduce the risk of getting HIV:
Croatian: Dok uzimate lijek Emtricitabin/tenofovirdizoproksil Mylan radi smanjenja rizika od dobivanja HIV-a:
English: STATEMENT OF ACTIVE SUBSTANCE
Croatian: 2. NAVOĐENJE DJELATNIH TVARI
English: How to store Emtricitabine/Tenofovir disoproxil Mylan
Croatian: Kako čuvati lijek Emtricitabin/tenofovirdizoproksil Mylan
English: Tenofovir disoproxil
Croatian: Tenofovirdizoproksil
English: NARCOTIC ANALGESICS Methadone/Tenofovir disoproxil
Croatian: Metadon/tenofovirdizoproksil
English: The safety of tenofovir disoproxil when used with sofosbuvir/velpatasvir/voxilaprevir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.
Croatian: Sigurnost tenofovirdizoproksila prilikom istovremene primjene sa sofosbuvirom/velpatasvirom/vo ksilaprevirom i farmakokinetičkim pojačivačem (npr. ritonavirom ili kobicistatom) nije ustanovljena.
English: BMD Z scores declined by 0.012 for lumbar spine and by 0.338 for total body in the 64 subjects who were treated with tenofovir disoproxil for 96 weeks.
Croatian: U 64 ispitanika koji su primali tenofovirdizoproksil tijekom 96 tjedana z-vrijednosti BMD-a smanjile su se za −0,012 u području lumbalne kralježnice, a z-vrijednosti BMD-a cijelog tijela smanjile su se za −0,338.
English: Placebo Emtricitabine/tenofovir disoproxil
Croatian: Placebo Emtricitabin/tenofovirdizoproksil P-vrijednosta,b
English: No dose adjustment of famciclovir is required.
Croatian: Nije potrebno prilagođivati dozu famciklovira.
English: A higher risk of renal impairment has been reported in HIV-1 infected patients receiving tenofovir disoproxil in combination with a ritonavir or cobicistat boosted protease inhibitor.
Croatian: U pacijenata zaraženih virusom HIV-1 koji su primali tenofovirdizoproksil u kombinaciji s ritonavirom ili kobicistatom pojačanim inhibitorom proteaze zabilježen je veći rizik od oštećenja funkcije bubrega.
English: Hepatitis C virus (HCV) antiviral agents Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.)
Croatian: Antivirusni lijekovi za virus hepatitisa C (HCV) Ledipasvir/sofosbuvir (90 mg/400 mg q.d.) + atazanavir/ritonavir (300 mg q.d./100 mg q.d.) + emtricitabin/tenofovirdizoproksil (200 mg/245 mg q.d.)1
English: Atazanavir/Ritonavir/Emtricitabine Interaction not studied.
Croatian: Atazanavir/ritonavir/emtricitabin
English: There are uncertainties associated with the long -term renal and bone effects of tenofovir disoproxil during the treatment of HIV-1 infection in the paediatric population.
Croatian: Pri liječenju infekcije virusom HIV-1 u pedijatrijskoj populaciji postoje nesigurnosti vezane uz dugoročne učinke tenofovirdizoproksila na bubrege i kosti.
English: • Know your hepatitis B virus (HBV) infection status before starting Emtricitabine/Tenofovir disoproxil Mylan.
Croatian: • Prije nego što počnete uzimati lijek Emtricitabin/tenofovirdizoproksil Mylan, morate znati jeste li zaraženi virusom hepatitisa B (HBV).
English: Bottle pack: Once opened use within 90 days.
Croatian: Boca: Iskoristiti unutar 90 dana od prvog otvaranja.
English: Renal management in HIV-1 infected patients
Croatian: Postupanje u slučaju sumnje na oštećenje bubrega u pacijenata zaraženih virusom HIV-1
English: Efavirenz/Tenofovir disoproxil
Croatian: Efavirenz/tenofovirdizoproksil
English: Emtricitabine: AUC: ↔ Cmax: ↔ Cmin: ↔
Croatian: Emtricitabin: AUC: ↔ Cmax: ↔ Cmin: ↔
English: Darunavir/Ritonavir/Emtricitabine Interaction not studied.
Croatian: Darunavir/ritonavir/emtricitabin
English: + Efavirenz/Emtricitabine/Tenofovir disoproxil (600 mg/200 mg/245 mg q.d.)
Croatian: Sofosbuvir (400 mg q.d.) + efavirenz/emtricitabin/ tenofovirdizoproksil (600 mg/200 mg/245 mg q.d.)
English: Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil, sofosbuvir/velpatasvir and lopinavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Croatian: Povećane koncentracije tenofovira u plazmi uslijed istovremene primjene tenofovirdizoproksila, sofosbuvira/velpatasvira i lopinavira/ritonavira mogu pojačati nuspojave vezane uz tenofovirdizoproksil, uključujući poremećaje bubrega.
English: Cmax: ↑ 55% (↑ 41 to ↑ 71) Cmin: ↑ 301% (↑ 257 to
Croatian: AUC: ↑ 142% (↑ 123 do ↑ 164) Cmax: ↑ 55% (↑ 41 do ↑ 71) Cmin: ↑ 301% (↑ 257 do ↑ 350)
English: asthenia
Croatian: Doziranje
English: (n = 1251)
Croatian: Emtricitabin/tenofovirdizoproksil (n = 1251)
English: pain, asthenia
Croatian: bol, astenija
English: rash
Croatian: osip
English: Transmission of HIV
Croatian: Prijenos HIV-a
English: Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil, sofosbuvir/velpatasvir and atazanavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Croatian: Povećane koncentracije tenofovira u plazmi uslijed istovremene primjene tenofovirdizoproksila, sofosbuvira/velpatasvira i atazanavira/ritonavira mogu pojačati nuspojave vezane uz tenofovirdizoproksil, uključujući poremećaje bubrega.
English: Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil, sofosbuvir/velpatasvir/voxilaprevir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Croatian: Povećane koncentracije tenofovira u plazmi uslijed istovremene primjene tenofovirdizoproksila, sofosbuvira/velpatasvira/voksila previra i darunavira/ritonavira mogu pojačati nuspojave vezane uz tenofovirdizoproksil, uključujući poremećaje bubrega.
English: Blister packs
Croatian: Blister
English: • Talk to your doctor if you are intolerant to lactose (see Emtricitabine/Tenofovir disoproxil Mylan contains lactose later in this section).
Croatian: • Ako ne podnosite laktozu, razgovarajte s liječnikom (pogledajte niže u ovom dijelu,
English: Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil, sofosbuvir/velpatasvir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Croatian: Povećane koncentracije tenofovira u plazmi uslijed istovremene primjene tenofovirdizoproksila, sofosbuvira/velpatasvira i darunavira/ritonavira mogu pojačati nuspojave vezane uz tenofovirdizoproksil, uključujući poremećaje bubrega.